RecruitingRecruiting
A Phase 1 Study of MVB-101 Administered Intraprostatically in Patients With Localized Prostate Cancer Who Are Scheduled for Radical Prostatectomy
NCT07944508 · MultiValent Biotherapies, Inc.
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
An Open-Label, Non-randomized, Multi-Center Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Bi-Ligand Drug Conjugate MVB-101 Injected Into the Prostate of Patients With Localized Cancer of the Prostate Who Are Scheduled for Prostatectomy
About this study
MVB-101 is a bi-ligand peptide-like drug conjugate targeting prostate-specific membrane antigen (PSMA) and folate receptor alpha (FR-alpha) and carrying monomethyl auristatin E (MMAE). MVB-101 will be administered by direct injection into the prostate under transrectal ultrasound guidance, at a fixed total injection volume of 10 mL (5 mL per lobe), once per week for 4 weeks.
Part A will enroll up to 30 participants. Planned dose levels are 1, 2, 4, and 8 mg per dose. The dose-limiting toxicity evaluation period is Day 1 through Day 29. Accelerated titration rules will be applied to the first two dose levels, and an i3+3 design will guide dose selection. Higher, lower, or intermediate dose levels may be added based on emerging data and Safety Monitoring Committee recommendations. The recommended Phase 2 dose may be the same as or lower than the maximum tolerated dose.
Part B will enroll up to 29 participants per dose group at one or more selected dose levels and will use a Simon two-stage design to better estimate the recommended Phase 2 dose and further characterize safety and preliminary efficacy.
The study includes screening, treatment, safety follow-up approximately 28 days after the last dose, post-treatment multiparametric MRI and PSA assessment, and planned radical prostatectomy at approximately Day 90 (12 weeks). If radical prostatectomy is not performed, a post-treatment prostate biopsy will be obtained as close as possible to the planned prostatectomy date. End of study occurs after completion of safety follow-up, post-treatment MRI and PSA assessment, and prostatectomy or post-treatment biopsy.
Eligibility criteria
Inclusion Criteria:
* Signed informed consent form.
* Understands the obligation and is capable of attending all follow-up visits.
* Documented, previously untreated, localized adenocarcinoma of the prostate confirmed by multiparametric MRI and prostate biopsy within 3 months before the first dose.
* Scheduled for radical prostatectomy approximately 12 weeks after the first dose of MVB-101.
* Gleason Grade Group 1 with at least one high-risk feature, or Grade Group 2, 3, or 4. High-risk features for Grade Group 1 are PSA density \>0.2 ng/mL/cc, PI-RADS 4 or 5, lesion \>1.0 cm, lesion volume \>0.4 cc, or risk of extraprostatic extension evidenced by capsular abutment or bulge.
* Prostate-specific antigen 20 ng/mL or less.
* Eastern Cooperative Oncology Group performance status 0 or 1.
* Adequate bone marrow and organ function.
* Sexually active participants agree to use barrier protection during treatment and for 1 month after the last MVB-101 dose.
Exclusion Criteria:
* Any prior treatment for prostate cancer, except prior active surveillance is permitted.
* More than 10 mg/day of systemic steroids within 28 days before signing informed consent.
* Prior exposure to auristatin, an auristatin derivative, or a similar molecule.
* Prior or concurrent malignancy whose natural history or treatment could interfere with or affect MVB-101 safety or efficacy assessments.
* Prostatic calcifications.
* Inability to undergo MRI scanning for any reason, including claustrophobia or implanted devices.
* Major surgery within 4 weeks before first dose or planned during the study, other than prostatectomy.
* Toxicity attributed to prior anticancer therapy, other than alopecia and fatigue, not resolved to Grade 1 or baseline before first dose.
* Poorly controlled concurrent disease, including diabetes or hypertension (systolic blood pressure \>160 mmHg or diastolic blood pressure \>100 mmHg).
* Within 12 months before enrollment: cardiac angioplasty or stenting, myocardial infarction, unstable angina, coronary artery bypass graft surgery, symptomatic peripheral vascular disease, or NYHA class III or IV congestive heart failure.
* History of clinically significant lung disease, including interstitial pneumonia, pneumonitis, pulmonary fibrosis, or severe radiation pneumonitis, or suspected disease on screening imaging.
* Active bleeding disorder or other history of Grade 3 or higher hemorrhage within 4 weeks before first dose.
* Need for oral vitamin K antagonist anticoagulant therapy. Low-dose anticoagulants to maintain central venous access patency or prevent deep venous thrombosis and therapeutic low-molecular-weight heparin are permitted.
* Deep vein thrombosis or pulmonary embolism within 6 months before first dose.
* Active infection requiring intravenous antibiotics within 1 week before first dose.
* Uncontrolled HIV, known AIDS, chronic hepatitis B, occult hepatitis B, or hepatitis C.
* Current or anticipated need for a strong CYP3A4 inhibitor or inducer. Prior use requires a washout of 21 days or 5 half-lives, whichever is longer, before first dose.
Study design
Enrollment target: 60 participants
Allocation: non_randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-08-14
Estimated completion: 2028-03
Last updated: 2026-11-18
Interventions
Drug: MVB-101
Primary outcomes
- • Treatment-emergent adverse events (From first dose through safety follow-up (approximately Day 50); treatment-related adverse events are followed through end of study (approximately Day 90))
- • Dose-limiting toxicities (Day 1 through Day 29)
- • Maximum tolerated dose (Through completion of Part A dose escalation, up to 12 months)
Sponsor
MultiValent Biotherapies, Inc. · industry
Contacts & investigators
ContactAimee Murphy · contact · amurphy@mvbiotx.com · 925-818-4403
InvestigatorStephen Snowdy, PhD · study_director, MultiValent Biotherapies, Inc.
All locations (2)
Urology Centers of AlabamaRecruiting
Homewood, Alabama, United States
Urology San AntonioRecruiting
San Antonio, Texas, United States